Last updated: May 29, 2026
MEFLOQUINE HYDROCHLORIDE Suppliers: Who Manufactures the API and Finished Drug, and How to Source Reliably
Suppliers for mefloquine hydrochloride span two supply tiers: (1) API producers that supply bulk mefloquine HCl and (2) finished-dose makers that sell mefloquine tablet products in regulated markets. A complete, decision-grade supplier map requires line-item evidence (company, site, product form, dossier references, and regulatory status in target countries). With only the drug name provided, a complete and accurate supplier list cannot be produced.
Who supplies mefloquine hydrochloride API (bulk) for pharma manufacturers?
No validated supplier set can be listed from the provided input. A reliable API supplier answer depends on current regulatory listings (e.g., FDA DMF status, WHO prequalification, EMA/EDQM catalog entries, or credible third-party verification) and confirmed commercial availability.
What API quality documents matter when sourcing mefloquine hydrochloride?
- DMF/ASMF availability and cross-reference pathways
- GMP certificate coverage for the specific dosage form and strength
- CoA traceability by batch
- Polymorph/hydrate control strategy and impurity profile for mefloquine HCl
Which companies sell mefloquine hydrochloride tablets (finished product) by market?
No finished-product supplier roster can be produced without target geography, strength (commonly 250 mg tablets in many markets), and approved label configuration. Supplier identification at country level is required because distributors and label holders vary by jurisdiction.
How do strength and label differences affect sourcing?
- Tablet strength and excipient system
- Packaging (blister vs bottle)
- Pharmacopoeial compliance statements
- Local regulatory sponsor name
What is the regulatory sourcing status of mefloquine hydrochloride in the US and EU?
No Orange Book / EU register interrogation results can be provided from the provided input. Regulatory status is the core discriminator for which suppliers can legally supply to a given market and which dossiers are actively referenced.
What regulatory datasets are typically used
- FDA Orange Book for US reference products and listed patents
- FDA drug master file (DMF) for API manufacturers
- EMA national authorization registers for EU-based supply chain mapping
What risks exist when sourcing mefloquine hydrochloride from non-validated suppliers?
A risk assessment requires known supplier names and their regulatory histories. Without supplier identifiers, risks cannot be mapped to specific entities.
Typical supply chain failure points
- Unsupported GMP scope for API or finished dose
- Incomplete impurity control for mefloquine HCl
- Batch-to-batch inconsistency tied to starting material supplier variation
- Regulatory non-compliance in target markets
How do mefloquine hydrochloride suppliers compare on quality, pricing, and lead times?
Comparative supplier scoring requires a supplier list plus auditable metrics (certificates, lead-time SLAs, MOQ, batch release timelines, and pricing terms).
What to benchmark
- GMP audit recency and findings
- DMF/ASMF status and holder reliability
- Niche capacity constraints and seasonal supply disruptions
- Variant control (particle size, polymorphic form, salt grade)
What should a pharma buyer require from mefloquine hydrochloride suppliers?
This section can’t be grounded in specific supplier commitments without company names. Still, the buyer checklist for mefloquine HCl sourcing is typically anchored to GMP and dossier traceability.
Procurement requirements that usually decide vendor qualification
- Written GMP compliance for API or finished product site
- Batch-specific CoA plus impurity panel matching specification
- Dossier linkage plan for the intended regulatory pathway
- Full quality agreement covering deviation handling and change control
What manufacturing/IP constraints could limit mefloquine hydrochloride sourcing?
IP constraints exist for both finished-dose formulations and certain processes, but identifying which constraints apply requires jurisdiction and product/patent mapping that cannot be done from the provided input.
Where constraints usually show up
- Process patents affecting crystallization, salt formation, or purification
- Method-of-use claims tied to indications and dosing regimens
- Regulatory exclusivities for specific reference products and strengths
Key Takeaways
- A decision-grade supplier list for mefloquine hydrochloride cannot be produced from the provided input.
- Reliable sourcing requires evidence-based mapping: API producers tied to regulatory dossiers and finished-dose suppliers tied to country-specific approved products.
- Supplier qualification must be anchored to GMP scope, dossier linkage (DMF/ASMF or equivalent), and batch release traceability for mefloquine hydrochloride.
FAQs
- Which countries have approved mefloquine hydrochloride tablets and which sponsors hold registrations?
- How do I verify an API manufacturer’s DMF status for mefloquine hydrochloride?
- What specification impurities are critical for mefloquine hydrochloride API release?
- What GMP documentation should be requested from mefloquine hydrochloride finished-dose suppliers?
- Can I source mefloquine hydrochloride from multiple API suppliers without regulatory change notifications?
References
- FDA. Drug Master Files (DMF). U.S. Food and Drug Administration.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- EMA. Human medicines registers and data. European Medicines Agency.
